Are central nervous system drugs displaying anti-inflammatory activity suitable for early treatment of COVID-19?
The majority of COVID-19 cases are only mildly or moderately symptomatic, but in some patients excessive inflammatory response becomes the dominant factor of disease progression to the advanced stage, with high mortality. Treatment with anti-inflammatory drugs either does not prevent disease progres...
Main Authors: | Paweł Grieb, Konrad Rejdak |
---|---|
Format: | Article |
Language: | English |
Published: |
Termedia Publishing House
2021-06-01
|
Series: | Folia Neuropathologica |
Subjects: | |
Online Access: | https://www.termedia.pl/Are-central-nervous-system-drugs-displaying-anti-inflammatory-r-nactivity-suitable-for-early-treatment-of-COVID-19-,20,44630,1,1.html |
Similar Items
-
Anti-Inflammatory Effects of Amantadine and Memantine: Possible Therapeutics for the Treatment of Covid-19?
by: Félix Javier Jiménez-Jiménez, et al.
Published: (2020-11-01) -
Anxiety and depression in COVID-19: treatment options
by: V. E. Medvedev
Published: (2021-04-01) -
Compulsive masturbation treated with fluvoxamine-A case study
by: B Rajshekhar, et al.
Published: (2010-01-01) -
"Efficacy of interferon and Amantadin for treatment of hepatitis in major thalasemia at Children’s Medical Center, Tehran "
by: Fallahi GHI, et al.
Published: (2007-04-01) -
Evaluation of the Effect of Antidepressant Drug, Fluvoxamine, on Cyclooxygenase-2 Protein Expression in Lipopolysaccharide-stimulated Macrophages
by: Hajar Naji Esfahani, et al.
Published: (2019-01-01)